Cite
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress.
MLA
Calbert, Marissa L., et al. “4’-Ethynyl-2’-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress.” Molecular Cancer Therapeutics, vol. 23, no. 5, May 2024, pp. 683–99. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-23-0487.
APA
Calbert, M. L., Chandramouly, G., Adams, C. M., Saez-Ayala, M., Kent, T., Tyagi, M., Ayyadevara, V. S. S. A., Wang, Y., Krais, J. J., Gordon, J., Atkins, J., Toma, M. M., Betzi, S., Boghossian, A. S., Rees, M. G., Ronan, M. M., Roth, J. A., Goldman, A. R., Gorman, N., … Pomerantz, R. T. (2024). 4’-Ethynyl-2’-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular Cancer Therapeutics, 23(5), 683–699. https://doi.org/10.1158/1535-7163.MCT-23-0487
Chicago
Calbert, Marissa L, Gurushankar Chandramouly, Clare M Adams, Magali Saez-Ayala, Tatiana Kent, Mrityunjay Tyagi, V S S Abhinav Ayyadevara, et al. 2024. “4’-Ethynyl-2’-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress.” Molecular Cancer Therapeutics 23 (5): 683–99. doi:10.1158/1535-7163.MCT-23-0487.